EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics

Md Nayab Sulaimani, Shazia Ahmed, Farah Anjum, Taj Mohammad, Anas Shamsi, Ravins Dohare iD, Md Imtaiyaz Hassan iD

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0311954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Md Nayab Sulaimani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Antineoplastic Agents, Mitogen-Activated Protein Kinase 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Human Resource Development Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitogen-activated protein kinase 1 (MAPK1) is a serine/threonine kinase that plays a crucial role in the MAP kinase signaling transduction pathway. This pathway plays a crucial role in various cellular processes, including cell proliferation, differentiation, adhesion, migration, and survival. Besides, many chemotherapeutic drugs targeting the MAPK pathway are used in clinical practice, and novel inhibitors of MAPK1 with improved specificity and efficacy are required. Hence, targeting MAPK1 can be crucial to control metastasis in cancer therapeutics. In this study, we utilized a structure-guided virtual screening approach to screen a library of thousands of natural compounds from the ZINC database. The Lipinski rule of five (RO5) was used as a criterion for the primary selection of natural compounds. The screened compounds were prioritized based on their binding affinity, docking scores, and specificity towards the kinase domain of MAPK1 during the molecular docking process. Subsequently, the selected hits underwent rigorous screening that included the identification of potential pan-assay interference compounds (PAINS), ADMET evaluation, and prediction of pharmacological activities using PASS analysis. Afterwards, we performed a comprehensive interaction analysis to explore the binding prototypes of the screened molecules with the key residues within the MAPK1 kinase domain. Finally, selected molecules underwent extensive all-atom molecular dynamics (MD) simulations for a time duration of 200 nanoseconds. The study pinpointed three natural compounds with ZINC database IDs ZINC0209285, ZINC02130647, and ZINC02133691 as potential inhibitors of MAPK1. The study highlights that these compounds could be explored further in preclinical and clinical investigations to develop anticancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinase 1Molecular Docking SimulationHumansMolecular Dynamics SimulationProtein Binding

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinase 1MAPK1 protein, human

Autor:innen und Institutionen

  • Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
  • Department of Computer Science, Jamia Millia Islamia, New Delhi, India.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
  • Center of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates.

ORCID-Profile: Ravins Dohare, Md Imtaiyaz Hassan

Förderung

  • Human Resource Development Group

Zitieren

APA

Sulaimani, M. N., Ahmed, S., Anjum, F., Mohammad, T., Shamsi, A., Dohare, R., & Hassan, M. I. (2025). Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics. PLOS ONE. https://doi.org/10.1371/journal.pone.0311954

Vancouver

Sulaimani MN, Ahmed S, Anjum F, Mohammad T, Shamsi A, Dohare R, et al. Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics. PLOS ONE. 2025. doi:10.1371/journal.pone.0311954

BibTeX
@article{Sulaimani2025,
  author = {Sulaimani, Md Nayab and Ahmed, Shazia and Anjum, Farah and Mohammad, Taj and Shamsi, Anas and Dohare, Ravins and Hassan, Md Imtaiyaz},
  title = {Structure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0311954}
}
Kostenlos starten →